PE20211446A1 - Formas de co-cristales de un analogo de novobiocina y prolina - Google Patents
Formas de co-cristales de un analogo de novobiocina y prolinaInfo
- Publication number
- PE20211446A1 PE20211446A1 PE2020001199A PE2020001199A PE20211446A1 PE 20211446 A1 PE20211446 A1 PE 20211446A1 PE 2020001199 A PE2020001199 A PE 2020001199A PE 2020001199 A PE2020001199 A PE 2020001199A PE 20211446 A1 PE20211446 A1 PE 20211446A1
- Authority
- PE
- Peru
- Prior art keywords
- novobiocin
- analog
- prolin
- crystals
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211446A1 true PE20211446A1 (es) | 2021-08-05 |
Family
ID=65444361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001199A PE20211446A1 (es) | 2018-02-07 | 2019-02-01 | Formas de co-cristales de un analogo de novobiocina y prolina |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10717755B2 (enExample) |
| EP (1) | EP3749675B1 (enExample) |
| JP (3) | JP2021512910A (enExample) |
| KR (2) | KR20240155354A (enExample) |
| CN (2) | CN112020506B (enExample) |
| AR (1) | AR114245A1 (enExample) |
| AU (3) | AU2019217821B2 (enExample) |
| BR (1) | BR112020016205A2 (enExample) |
| CA (2) | CA3226385A1 (enExample) |
| CL (2) | CL2020002051A1 (enExample) |
| CO (1) | CO2020009761A2 (enExample) |
| EA (1) | EA202091885A1 (enExample) |
| IL (2) | IL315865A (enExample) |
| MX (2) | MX2020008326A (enExample) |
| MY (1) | MY209803A (enExample) |
| PE (1) | PE20211446A1 (enExample) |
| SG (1) | SG11202007530XA (enExample) |
| TW (3) | TWI868593B (enExample) |
| WO (1) | WO2019156907A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021512910A (ja) * | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011306391B2 (en) * | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| CN104159584A (zh) * | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| NZ629778A (en) * | 2012-02-09 | 2016-03-31 | Univ Kansas | C-terminal hsp90 inhibitors |
| US9556216B2 (en) * | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| CN106536498A (zh) | 2014-06-24 | 2017-03-22 | 堪萨斯大学 | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 |
| PL3202772T3 (pl) | 2014-09-30 | 2021-02-22 | Jiangsu Hengrui Medicine Co. Ltd. | Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 |
| JP2021512910A (ja) | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
-
2019
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja active Pending
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-01 TW TW113147071A patent/TWI915111B/zh active
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002959A1 (es) | Nuevas formas sólidas de ácido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7- hidroxi-1-propil-1,2,3,4,4a,5,10,10a- octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro2h-piran-2-carboxílico. | |
| ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| CO2021009240A2 (es) | Compuestos moduladores de fxr (nr1h4) | |
| CO2022015930A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CR20220559A (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
| MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
| CL2012001461A1 (es) | Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras. | |
| MX2014000534A (es) | Nuevos compuestos que se unen a fxr (nr1h4) y modulan. | |
| NZ629778A (en) | C-terminal hsp90 inhibitors | |
| BRPI0817096A8 (pt) | Análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| CL2004000732A1 (es) | Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer. | |
| AR096582A1 (es) | Procesos de fabricación y formas cristalinas de un inhibidor de mdm2 | |
| CO6761374A2 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| MX2024015708A (es) | Moduladores del trem2 | |
| CL2020002051A1 (es) | Formas de co-cristales de un análogo de novobiocina y prolina.- | |
| DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| CL2022003187A1 (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| PE20231440A1 (es) | Formas solidas de un compuesto | |
| FI3774745T3 (fi) | Oksatsoliyhdistekide | |
| MY210277A (en) | Compounds having s1p5 receptor agonistic activity | |
| GT200700020A (es) | Compuestos y derivados de dibencilamina | |
| CL2020001928A1 (es) | Formas cristalinas del antagonista del receptor cxcr7 ácido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico (1-pirimidin-2-il-ciclopropil)-amida. | |
| NZ767558B2 (en) | Co-crystal forms of a novobiocin analog and proline |